{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-24-000007","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.982217+00:00","generated_at":"2026-06-06T13:10:53.407639+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kiora licenses KIO-301 to Théa for up to $301M; $16M upfront, milestones, royalties","bullets":["$16M upfront; up to $285M in milestones and tiered royalties up to low 20% on net sales.","TOI gets exclusive worldwide rights (ex-Asia) for retinitis pigmentosa and other ophthalmic uses.","Kiora responsible for Phase 2 design; TOI for Phase 3 and commercialization.","Phase 1/2 ABACUS data showed meaningful vision improvements; Phase 2 starts early 2024.","Investor webcast scheduled for Jan 31, 2024 at 5:30 pm ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-24-000007","json":"https://secwatch.observer/filing/0001372514-24-000007.json","markdown":"https://secwatch.observer/filing/0001372514-24-000007.md","text":"https://secwatch.observer/filing/0001372514-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000007/0001372514-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000007/kprx-20240125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T13:10:53.407639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44d6889df0ff98ef648d4058f14ad0c83dff6d4e","claim":"KIORA PHARMACEUTICALS INC entered into Exclusive License and Development Agreement with Théa Open Innovation SAS valued at up-front payment of $16.0 million (effective 2024-01-25).","evidence_excerpt":"On January 25, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License and Development Agreement (the “Agreement”) with Théa Open Innovation SAS (“TOI”) with respect to the Company’s KIO-301 molecular photoswitch product (the “Product”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000007/0001372514-24-000007-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Théa Open Innovation SAS"},{"label":"Value","value":"up-front payment of $16.0 million"},{"label":"Effective","value":"2024-01-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}